Unsupervised analysis of combined lipid and coagulation data reveals coagulopathy subtypes among dialysis patients
Hemodialysis (HD) and peritoneal dialysis (PD) are the primary means of managing end stage renal disease (ESRD). However, these treatment modalities are associated with the onset of coagulation abnormalities. Effective management of coagulation risk among these patients requires the identification o...
Main Authors: | , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2017-03-01
|
Series: | Journal of Lipid Research |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S0022227520304521 |
id |
doaj-802bf30a12c84747b2f2c7abb81d1889 |
---|---|
record_format |
Article |
spelling |
doaj-802bf30a12c84747b2f2c7abb81d18892021-04-29T04:34:13ZengElsevierJournal of Lipid Research0022-22752017-03-01583586599Unsupervised analysis of combined lipid and coagulation data reveals coagulopathy subtypes among dialysis patientsDaniel Contaifer, Jr.0Daniel E. Carl1Urszula Osinska Warncke2Erika J. Martin3Bassem M. Mohammed4Benjamin Van Tassell5Donald F. Brophy6Charles E. Chalfant7Dayanjan S. Wijesinghe8Department of Pharmacotherapy and Outcomes Science, School of Pharmacy, Virginia Commonwealth University (VCU), Richmond, VADepartments of Internal Medicine, Virginia Commonwealth University (VCU), Richmond, VADepartment of Pharmacotherapy and Outcomes Science, School of Pharmacy, Virginia Commonwealth University (VCU), Richmond, VADepartment of Pharmacotherapy and Outcomes Science, School of Pharmacy, Virginia Commonwealth University (VCU), Richmond, VADepartment of Pharmacotherapy and Outcomes Science, School of Pharmacy, Virginia Commonwealth University (VCU), Richmond, VADepartment of Pharmacotherapy and Outcomes Science, School of Pharmacy, Virginia Commonwealth University (VCU), Richmond, VADepartment of Pharmacotherapy and Outcomes Science, School of Pharmacy, Virginia Commonwealth University (VCU), Richmond, VA; To whom correspondence should be addressed.Biochemistry and Molecular Biology, Virginia Commonwealth University (VCU), Richmond, VA; Hunter Holmes McGuire Veterans Administration Medical Center, VCU Johnson Center for Critical Care Research, VCU Massey Cancer Center, and VCU Institute of Molecular Medicine, Richmond, VA; To whom correspondence should be addressed.Department of Pharmacotherapy and Outcomes Science, School of Pharmacy, Virginia Commonwealth University (VCU), Richmond, VA; Surgery, Virginia Commonwealth University (VCU), Richmond, VA; To whom correspondence should be addressed.Hemodialysis (HD) and peritoneal dialysis (PD) are the primary means of managing end stage renal disease (ESRD). However, these treatment modalities are associated with the onset of coagulation abnormalities. Effective management of coagulation risk among these patients requires the identification of surrogate markers that provide an early indication of the coagulation abnormalities. The role of sphingolipids in the manifestation and prediction of coagulation abnormalities among dialysis patients have never been investigated. Herein, we report the first instance of an in depth investigation into the sphingolipid changes among ESRD patients undergoing HD and PD. The results reveal distinct differences in terms of perturbations to specific sphingolipid biosynthetic pathways that are highly dependent on the treatment modality. Our studies also demonstrated strong correlation between specific sphingolipids and coagulation parameters, such as HexCer(d18:1/26:0) and maximal amplitude (MA), SM(d18:1/24:1) and tissue factor pathway inhibitor, and sphingosine 1-phosphate d18:1 and FX (Spearman ρ of 0.93, 0.89, and −0.89, respectively). Furthermore, our study revealed the potential for using HexCer(d18:1/22:0), HexCer(d18:1/24:0), and HexCer(d18:1/26:0) (r2 = 0.71, 0.82, and 0.63, respectively) and coagulation parameter MA (r2 = 0.7) for successful diagnosis of differential coagulopathies among ESRD patients undergoing HD, providing an opportunity toward personalized disease management.http://www.sciencedirect.com/science/article/pii/S0022227520304521coagulopathyrenal diseasesphingolipidsmonohexosyl ceramidesphingomyelinsphingosine 1-phosphate |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Daniel Contaifer, Jr. Daniel E. Carl Urszula Osinska Warncke Erika J. Martin Bassem M. Mohammed Benjamin Van Tassell Donald F. Brophy Charles E. Chalfant Dayanjan S. Wijesinghe |
spellingShingle |
Daniel Contaifer, Jr. Daniel E. Carl Urszula Osinska Warncke Erika J. Martin Bassem M. Mohammed Benjamin Van Tassell Donald F. Brophy Charles E. Chalfant Dayanjan S. Wijesinghe Unsupervised analysis of combined lipid and coagulation data reveals coagulopathy subtypes among dialysis patients Journal of Lipid Research coagulopathy renal disease sphingolipids monohexosyl ceramide sphingomyelin sphingosine 1-phosphate |
author_facet |
Daniel Contaifer, Jr. Daniel E. Carl Urszula Osinska Warncke Erika J. Martin Bassem M. Mohammed Benjamin Van Tassell Donald F. Brophy Charles E. Chalfant Dayanjan S. Wijesinghe |
author_sort |
Daniel Contaifer, Jr. |
title |
Unsupervised analysis of combined lipid and coagulation data reveals coagulopathy subtypes among dialysis patients |
title_short |
Unsupervised analysis of combined lipid and coagulation data reveals coagulopathy subtypes among dialysis patients |
title_full |
Unsupervised analysis of combined lipid and coagulation data reveals coagulopathy subtypes among dialysis patients |
title_fullStr |
Unsupervised analysis of combined lipid and coagulation data reveals coagulopathy subtypes among dialysis patients |
title_full_unstemmed |
Unsupervised analysis of combined lipid and coagulation data reveals coagulopathy subtypes among dialysis patients |
title_sort |
unsupervised analysis of combined lipid and coagulation data reveals coagulopathy subtypes among dialysis patients |
publisher |
Elsevier |
series |
Journal of Lipid Research |
issn |
0022-2275 |
publishDate |
2017-03-01 |
description |
Hemodialysis (HD) and peritoneal dialysis (PD) are the primary means of managing end stage renal disease (ESRD). However, these treatment modalities are associated with the onset of coagulation abnormalities. Effective management of coagulation risk among these patients requires the identification of surrogate markers that provide an early indication of the coagulation abnormalities. The role of sphingolipids in the manifestation and prediction of coagulation abnormalities among dialysis patients have never been investigated. Herein, we report the first instance of an in depth investigation into the sphingolipid changes among ESRD patients undergoing HD and PD. The results reveal distinct differences in terms of perturbations to specific sphingolipid biosynthetic pathways that are highly dependent on the treatment modality. Our studies also demonstrated strong correlation between specific sphingolipids and coagulation parameters, such as HexCer(d18:1/26:0) and maximal amplitude (MA), SM(d18:1/24:1) and tissue factor pathway inhibitor, and sphingosine 1-phosphate d18:1 and FX (Spearman ρ of 0.93, 0.89, and −0.89, respectively). Furthermore, our study revealed the potential for using HexCer(d18:1/22:0), HexCer(d18:1/24:0), and HexCer(d18:1/26:0) (r2 = 0.71, 0.82, and 0.63, respectively) and coagulation parameter MA (r2 = 0.7) for successful diagnosis of differential coagulopathies among ESRD patients undergoing HD, providing an opportunity toward personalized disease management. |
topic |
coagulopathy renal disease sphingolipids monohexosyl ceramide sphingomyelin sphingosine 1-phosphate |
url |
http://www.sciencedirect.com/science/article/pii/S0022227520304521 |
work_keys_str_mv |
AT danielcontaiferjr unsupervisedanalysisofcombinedlipidandcoagulationdatarevealscoagulopathysubtypesamongdialysispatients AT danielecarl unsupervisedanalysisofcombinedlipidandcoagulationdatarevealscoagulopathysubtypesamongdialysispatients AT urszulaosinskawarncke unsupervisedanalysisofcombinedlipidandcoagulationdatarevealscoagulopathysubtypesamongdialysispatients AT erikajmartin unsupervisedanalysisofcombinedlipidandcoagulationdatarevealscoagulopathysubtypesamongdialysispatients AT bassemmmohammed unsupervisedanalysisofcombinedlipidandcoagulationdatarevealscoagulopathysubtypesamongdialysispatients AT benjaminvantassell unsupervisedanalysisofcombinedlipidandcoagulationdatarevealscoagulopathysubtypesamongdialysispatients AT donaldfbrophy unsupervisedanalysisofcombinedlipidandcoagulationdatarevealscoagulopathysubtypesamongdialysispatients AT charlesechalfant unsupervisedanalysisofcombinedlipidandcoagulationdatarevealscoagulopathysubtypesamongdialysispatients AT dayanjanswijesinghe unsupervisedanalysisofcombinedlipidandcoagulationdatarevealscoagulopathysubtypesamongdialysispatients |
_version_ |
1721502616302649344 |